EV20/MMAF

N/A

Report date: 2024/02/05 14:03:43

Base Information

Drug NameEV20/MMAF

Drug Alias NameEV20/MMAF

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linker > MC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAF payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionReceptor tyrosine-protein kinase erbB-3 antagonists

TargetsReceptor tyrosine-protein kinase erbB-3

Therapy Area/IndicationsSkin Melanoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryItaly

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesMedia Pharma SRL

China Registration ClassN/A

Develop Information

Active CompaniesMedia Pharma SRL

Inactive CompaniesN/A

Active IndicationsSkin Melanoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A